5:58 PM
 | 
Feb 04, 2013
 |  BC Extra  |  Top Story

Gilead reports more Phase III HCV data

Gilead Sciences Inc. (NASDAQ:GILD) reported top-line data on Monday from a pair of Phase III trials evaluating sofosbuvir ( GS-7977) in treatment-naïve HCV patients. In the FISSION trial in patients with chronic HCV genotype 2 and 3 infection, once-daily sofosbuvir plus ribavirin for 12 weeks met the primary endpoint of non-inferiority to interferon plus ribavirin for 24 weeks in the proportion of patients achieving a sustained virologic response (SVR) 12 weeks after the end of treatment. Sofosbuvir plus ribavirin led...

Read the full 390 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >